The tests are used to detect Epstein-Barr virus DNA levels, linked to a range of diseases including cancer. The tests had previously been granted a breakthrough device designation by the FDA.
(Reporting by John Revill; Editing by Kim Coghill)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
219.8 CHF | +0.43% | -1.04% | -10.10% |
Apr. 25 | The specter of stagflation rears its ugly head again | |
Apr. 25 | ROCHE : Barclays lowers target price | CF |
Roche has received authorisation from the United States' Food and Drug Administration (FDA) for its cobas 6800/8800 diagnostic tests for transplant patients, the company said on Wednesday.
The tests are used to detect Epstein-Barr virus DNA levels, linked to a range of diseases including cancer. The tests had previously been granted a breakthrough device designation by the FDA.
(Reporting by John Revill; Editing by Kim Coghill)
1st Jan change | Capi. | |
---|---|---|
-10.10% | 193B | |
+24.29% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.11% | 233B | |
+5.51% | 201B | |
-12.26% | 143B | |
-6.47% | 144B | |
+1.45% | 123B |